Background: Recent data suggest that major depression is potentially associated with dysregulated cytokine production. However, the roles of T helper (Th) cells and their subsets in the development of depression still remain to be determined. The present study assessed changes in Th cell subsets and cytokines during the development of depression in a mouse model. Methods: Chronic unpredictable mild stress (CUMS) was used to simulate depression behavior in mice. The open field test, sucrose preference, and ingestion were used as evaluative indicators of depressive behavior. During the CUMS protocol, on days 3, 7, 14, and 21, we assessed behavioral changes, cytokine levels in serum or stimulated (CD3/CD28) cell culture medium, and mRNA expression (ELISA, RT-PCR), regulatory T (Treg) and Th17 subsets in spleen (ex vivo, flow cytometry, RT-PCR), and CD3/rIL-23-stimulated Th17 cell proliferation (MTT assay). Results: The results showed that in the depression model mice, IL-4 mRNA expression and serum levels increased on day 7, while no detectable change was observed in IFN-γ. Notably, a reduced proportion of Th17 cells with decreased proliferation capacity was observed at later stages, in parallel with a decline in serum IL-23 levels. In contrast, an increased Treg cell proportion and increased Foxp3 mRNA expression were observed in the mid-stages. Correlation analysis showed that the proportion of Tregs was correlated negatively with sucrose preference, while the proliferation of Th17 cells was notably correlated positively with sucrose preference. Also, an increased TGF-β level was detected in serum and was believed to be a key factor responsible for the imbalance between Th17 and Treg cells. Furthermore, the sucrose preference in TGF-β type I receptor blockade mice increased considerably, compared with CUMS mice. Conclusion: These results indicate that in CUMS-induced depression, behavioral changes may closely correlate with the imbalance between Th17 and Treg cell subsets, and TGF-β may be a key regulatory cytokine.

Keywords:
Depression, Chronic unpredictable mild stress, Treg, Th17, TGF-β
1.
World Health Organization: The Global Burden of Disease: 2004 Update. 2008, p 153.
2.
Schildkraut JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509–522.
3.
Steffens DC, Byrum CE, McQuoid DR, Greenberg DL, Payne ME, Blitchington TF, MacFall JR, Krishnan KR: Hippocampal volume in geriatric depression. Bio Psychiatry 2000;48:301–309.
4.
Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R: Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci 2004;29:208–218.
5.
Elhwuegi AS: Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:435–451.
6.
Scholl JL, Renner KJ, Forster GL, Tejani-Butt S: Central monoamine levels differ between rat strains used in studies of depressive behavior. Brain Res 2010;1355:41–51.
7.
Irwin MR, Miller AH: Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007;21:374–383.
8.
Blume J, Douglas SD, Evans DL: Immune suppression and immune activation in depression. Brain Behav Immun 2011;25:221–229.
9.
Dunn A J, Swiergiel A H, de Beacurepaire R: Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 2005;29:891–909.
10.
Maes M, Scharpe S, Meltzer HY, Okayli G, Bosmans E, D’Hondt P, Vanden Bossche BV, Cosyns P: Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994;54:143–160.
11.
Zorrilla EP, Luborsky L, Mckay JR, et al: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001;15:199–226.
12.
Glaser R, Kiecolt-Glaser JK: Stress-induced immune dysfunction: implications for health. Nat Rev Immunol 2005;5:243–251.
13.
Saul AN, Oberyszyn TM, Daugherty C, Kusewitt D, Jones S, Jewell S, Malarkey WB, Lehman A, Lemeshow S, Dhabhar FS: Chronic stress and susceptibility to skin cancer. J Natl Cancer Inst 2005;97:1760–1767.
14.
Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H: Cytokine production and serum proteins in depression. Scand J Immunol 1995;41:534–538.
15.
Myint AM, Leonard BE, Steinbusch HW, Kim YK: Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 2005;88:167–173.
16.
Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, Sanisoglu SY, Yesilova Z, Ozmenler N, Ozsahin A, Sengul A: Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007;2007:76396.
17.
Miller AH: Depression and immunity: a role for T cells? Brain Behav Immun 2010;24:1–8.
18.
Schleifer SJ, Keller SE, Bond RN, Cohen J, Stein M: Major depressive disorder and immunity. Role of age, sex, severity, and hospitalization. Arch Gen Psychiatry 1989;46:81–87.
19.
Pal SN, Dandiya PC: Comparative study of diazepam, mapratroline, fluvoxamine, trazodone and alprazolam in some animal models of depression. Indian J Pharmacol 1993;25:204–208.
20.
Nirmal J, Babu CS, Harisudhan T, Ramanathan M: Evaluation of behavioural and antioxidant activity of Cytisus scoparius Link in rats exposed to chronic unpredictable mild stress. BMC Complement Altern Med 2008;8:15.
21.
Willner P, Towell A, Sampson D, Sophokleous S, Muscat R: Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987;93:358–364.
22.
Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, Nussenblatt RB, Caspi RR: Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol 2008;180:5167–5171.
23.
Li Q, Furman SA, Bradford CR, Chang AE: Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation. Clin Cancer Res 1999;5:461–469.
24.
McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O’Shea JJ, Cua DJ: The interleukin 23 receptor is essential for terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009;10:314–324.
25.
Ouyang Y, Miyata M, Hatsushika K, Ohnuma Y, Katoh R, Ogawa H, Okumura K, Masuyama K, Nakao A: TGF-beta signaling may play a role in the development of goblet cell hyperplasia in a mouse model of allergic rhinitis. Allergol Int 2010;59:313–319.
26.
Leonard BE: The concept of depression as a dysfunction of the immune system. Curr Immunol Rev 2010;6:205–212.
27.
Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995;34:301–309.
28.
Raison C L, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24–31.
29.
Frasure-Smith N, Lespérance F, Irwin MR, Sauvé C, Lespérance J, Théroux P: Depression, C-reactive protein and two-year major adverse cardiac events in men after acute coronary syndromes. Bio Psychiatry 2007;62:302–308.
30.
Willner P: Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:677–690.
31.
Willner P: Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52:90–110.
32.
Fearon DT, Locksley RM: The instructive role of innate immunity in the acquired immune response. Science 1996;272:50–53.
33.
Medzhitov R, Janeway CA Jr: Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998;10:351–353.
34.
Del Prete G: Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. Allergy 1992;47:450–455.
35.
Schwarz M J, Chiang S, Müller N, Ackenheil M: T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 2001;15:340–370.
36.
Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H: Increased CD56+ natural killer cells and related cytokines in major depression. Clin Immunol Immunopathol 1996;78:83–85.
37.
Mendlovic S, Mozes E, Eilat E, Doron A, Lereya J, Zakuth V, Spirer Z: Immune activation in non-treated suicidal major depression. Immunol Lett 1999;67:105–108.
38.
Kubo M, Yamashita M, Abe R, Tada T, Okumura K, Ransom J T, Nakayama T: CD28 costimulation accelerates IL-4 receptor sensitivity and IL-4-mediated Th2 differentiation. J Immunol 1999;163:2432–2442.
39.
Kim YK, Na KS, Shin KH, et al: Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1044–1053.
40.
Pavón L, Sandoval-López G, Eugenia-Hernández M, Loría F, Estrada I, Pérez M, Moreno J, Avila U, Leff P, Antón B, Heinze G: Th2 cytokine response in Major Depressive Disorder patients before treatment. J Neuroimmunol 2006;172:156–165.
41.
Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233–240.
42.
Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715–725.
43.
Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DA: The development and function of regulatory T cells. Cell Mol Life Sci 2009;66:2603–2622.
44.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46–56.
45.
Witowski J, Ksiazek K, Jörres A: Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 2004;61:567–579.
46.
Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG: Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125–130.
47.
McKenzie BS, Kastelein RA, Cua DJ: Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27:17–23.
48.
Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM: Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677–688.
49.
Weaver CT, Hatton RD, Mangan PR, Harrington LE: IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821–852.
50.
Kimura A, Kishimoto T: Th17 cells in inflammation. Int Immunopharmacol 2011;11:319–322.
51.
Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR: TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008;453:236–240.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.